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ABSTRACT
Patient-derived induced pluripotent stem cells (iPSCs) provide an
opportunity to study human diseases mainly in those cases for which
no suitable model systems are available. Here, we have taken
advantage of in vitro iPSCs derived from patients affected by
amyotrophic lateral sclerosis (ALS) and carrying mutations in the
RNA-binding protein FUS to study the cellular behavior of the mutant
proteins in the appropriate genetic background. Moreover, the ability
to differentiate iPSCs into spinal cord neural cells provides an in vitro
model mimicking the physiological conditions. iPSCs were derived
from FUSR514S and FUSR521C patient fibroblasts, whereas in the case
of the severe FUSP525L mutation, in which fibroblasts were not
available, a heterozygous and a homozygous iPSC line were raised
by TALEN-directed mutagenesis. We show that aberrant localization
and recruitment of FUS into stress granules (SGs) is a prerogative
of the FUS mutant proteins and occurs only upon induction of stress
in both undifferentiated iPSCs and spinal cord neural cells. Moreover,
we show that the incorporation into SGs is proportional to the
amount of cytoplasmic FUS, strongly correlating with the cytoplasmic
delocalization phenotype of the different mutants. Therefore, the
available iPSCs represent a very powerful system for understanding
the correlation between FUS mutations, the molecular mechanisms
of SG formation and ALS ethiopathogenesis.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease caused by loss of motoneurons (MNs) in the spinal cord
and brain, leading to progressive muscle atrophy. About 10% of
ALS cases are familial (fALS), whereas the rest is sporadic
(sALS). Several genes have been linked to familial and sporadic
ALS. Among them, Cu/Zn superoxide dismutase 1 (SOD1),
chromosome 9 open reading frame 72 (C9orf72 – Human Gene
Nomenclature Database), Tar DNA-binding protein 43 (TDP-43;
TARDBP – Human Gene Nomenclature Database) and fused in
sarcoma/translocated in liposarcoma (FUS/TLS or FUS) account
for most fALS cases (Renton et al., 2014). FUS and TDP-43 are
both RNA-binding proteins with a role in multiple steps of RNA
processing (Lagier-Tourenne et al., 2010). This suggests a
common mechanism underlying their involvement in ALS.
However, a clear correlation between the genetic defect and the
physiopathology of the disease remains elusive. Both FUS and
TDP-43 are mainly localized in the nucleus but shuttle between
the nucleus and the cytosol (Zinszner et al., 1997; Ayala et al.,
2008). A hallmark of the pathology is the presence of cytoplasmic
inclusions of mutated proteins in the brain (including frontal
cortex, substantia nigra, amygdala and cingulate gyrus) and spinal
cord of FUS (Kwiatkowski et al., 2009; Vance et al., 2009) and
TDP-43 (Yokoseki et al., 2008; Van Deerlin et al., 2008) patients.
Many ALS-associated FUS mutations disrupt the function of the
C-terminal PY domain, which serves as a nuclear localization
signal (NLS) (Vance et al., 2009, 2013; Gal et al., 2011; Dormann
et al., 2010; Bosco et al., 2010; Ito et al., 2010; Kino et al., 2011).
Defects in nuclear import, leading to aberrant cytoplasmic
localization of FUS, have been proposed as the initial step in
ALS pathogenesis (Bentmann et al., 2013).
So far, it is unclear whether reducedMN survival in ALS patients
is due to loss of a nuclear function or gain of a still unidentified toxic
function in the cytoplasm, or a combination of both (Lagier-
Tourenne et al., 2010). Increased oxidative stress is thought to play a
role in ALS pathogenesis, and FUS and TDP-43 cytoplasmic
inclusions co-localize with stress granule (SG) markers in ALS
patients (Ferrante et al., 1997; Liu-Yesucevitz et al., 2010;
Bentmann et al., 2012). SGs form in the cytoplasm upon
exposure to several kinds of stress. They represent mRNA storage
and sorting compartments that protect the cell by allowing
prioritized translation of stress-response genes. FUS, TDP-43 and
other RNA-binding proteins involved in ALS (such as EWS/
EWSR1, TAF15 and ATXN2) can be found in SGs and/or regulate
SG assembly (Bentmann et al., 2013). It has been proposed that SGs
play a role in neurodegeneration as possible precursors of
pathological inclusions (Bentmann et al., 2013; Wolozin, 2012).
Even though transient SGs have a protective function in normal
neurons, mutations in their components might convert them into
overly stable structures (Wolozin, 2012). In the case of ALS patients
with TDP-43 and FUS mutations, trapping of these pleiotropic
RNA-binding proteins in permanent inclusions might result in loss
of crucial regulation of RNA splicing, maturation and transport,
and/or gain of a toxic function.
So far, the molecular analysis of ALS pathogenesis has
been hampered by the lack of suitable cell model systems.
Reprogramming of human somatic cells into induced pluripotent
stem cells (iPSCs) provides a unique opportunity for disease
modeling in vitro. iPSCs can be derived from patients harboring a
disease-associated mutation (patient-specific iPSCs, PS-iPSCs) andReceived 20 January 2015; Accepted 20 April 2015
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then differentiated into (virtually) any cell type (Stadtfeld and
Hochedlinger, 2010). Thus, iPSC-based models represent a new
powerful tool to study the mechanisms underlying the
pathophysiology of neurodegenerative diseases in the context
of human neurons (Sandoe and Eggan, 2013). The potential of
iPSCs can be further expanded by the possibility to edit their
genome by site-directed mutagenesis. Several tools are now
available for genetic engineering in iPSCs, including systems
based on transcription activator-like effector nucleases (TALENs)
(Hockemeyer et al., 2011) and on clustered regularly interspaced
short palindromic repeats (CRISPR)/Cas9 (Mali et al., 2013).
Several groups have reported the characterization of iPSCs derived
from fALS individuals with mutations in the SOD1 and TDP-43
genes (Dimos et al., 2008; Boulting et al., 2011; Bilican et al., 2012;
Egawa et al., 2012). Importantly, iPSCs could be derived from older
individuals, and the mutations in ALS-associated genes did not
impair their ability to differentiate into MNs (Dimos et al., 2008).
MNs with TDP-43 mutations displayed cytosolic aggregates and
decreased survival in vitro, in particular upon addition of a cellular
stressor, such as sodium arsenite that induces oxidative stress
(Bilican et al., 2012; Egawa et al., 2012).
Incorporation of FUS into SGs in response to stress has been
studiedmostly in cell lines ectopically expressingmutant orwild-type
(WT) proteins (Gal et al., 2011; Dormann et al., 2010, 2012; Bosco
et al., 2010; Ito et al., 2010; Vance et al., 2013; Baron et al., 2013;
Shelkovnikova et al., 2013), or, more recently, in ALS patients’
fibroblasts (Vance et al., 2013). In this study, we aimed at generating a
cell system, which would be more relevant to the pathology and in
which FUS mutants are expressed endogenously at physiological
levels. We generated iPSC lines from two ALS patients with FUS
mutations, along with two controls: one from a healthy individual,
devoid of mutations in FUS and TDP-43, and one from an age-
matched patient with a mutation in TDP-43, to serve as a non-FUS
ALS iPSC line. By TALEN-directed mutagenesis we also produced
two additional mutant lines, carrying in homozygosis or
heterozygosis the FUS P525L mutation associated with a severe
and juvenile ALS form. We show here that different kinds of stress,
including oxidative, heat and osmotic stress, induce preferential
recruitment of mutant FUS in SGs both in undifferentiated iPSCs and
differentiated ventral spinal cord neural populations, including MNs.
Levels of FUS within SGs correlated with the degree of cytoplasmic
delocalization of mutant proteins in unstressed conditions.
RESULTS
Generation of iPSCs from ALS patients’ fibroblasts
ALS patients harboring mutations in the FUS or TDP-43 genes
were recruited in order to obtain skin biopsies. Informed donors
included three individuals with different heterozygous mutations in
FUS, R514S (ALS I–FUSR514S/wt; age 49; female), R521C (ALS II–
FUSR521C/wt; age 39; male) (Chiò et al., 2011) and P525L (ALS IV–
FUSP525L/wt; age 20; female), and one individual with a homozygous
A382T mutation in the TDP-43 gene (ALS III–FUSA382T/A382T; age
50; male) (Borghero et al., 2011).
From the biopsies we derived primary dermal fibroblasts.
Fibroblasts from a healthy individual (age 8), devoid of mutations in
FUS and TDP-43 (supplementary material Fig. S1), served as control
(WT I). Patients and control cells were reprogrammed into iPSCs
by taking advantage of a single lentiviral vector constitutively
expressing the four human reprogramming factors, OCT4 (POU5F1
– Human Gene Nomenclature Database), KLF4, SOX2 and cMYC
(hSTEMCCA) (Somers et al., 2010). iPSC-like colonies were
obtained from control and ALS I, ALS II and ALS III fibroblasts,
but not from ALS IV (see Materials and Methods for details).
After reprogramming, single iPSC-like colonies with uniform flat
morphology and defined borders were selected for expansion as
individual clones. Several clones per line were then validated as
bona fide iPSCs. Expression of pluripotency markers was assessed
by immunostaining (OCT4, SSEA4 and TRA1-60; Fig. 1A) and by
real-time RT-PCR (RT-qPCR) (NANOG, REX1, SOX2,
DNMT3B; Fig. 1B and supplementary material Fig. S1A). We
also confirmed that expression of the exogenous reprogramming
factor gene OCT4 was silenced upon reprogramming, with a
corresponding upregulation of its endogenous counterpart (Fig. 1C
and supplementary material Fig. S1B). Pluripotency of the new
iPSC lines was verified by multi-lineage differentiation assays
in vitro. RT-PCR analysis showed induction of ectoderm, mesoderm
and endoderm markers (supplementary material Fig. S1C). Finally,
sequencing of FUS and TDP-43 confirmed the presence of the
expected mutations in iPSC lines derived from the respective
RESOURCE IMPACT
Background
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease
caused by loss of motoneurons, leading to progressive muscle atrophy.
The majority of cases are sporadic; however, several genes have been
recently linked to ALS, including the fused in sarcoma/translocated in
liposarcoma (FUS) gene. Whereas wild-type FUS protein is
predominantly nuclear, ALS-associated mutations cause its
cytoplasmic delocalization. FUS cytoplasmic inclusions are found in the
brain and spinal cord of individuals with ALS. However, the link between
FUS mutations and motoneuron death is currently missing. In rodent
models, overexpression of either mutant or wild-type FUS seems to exert
similar outcomes, pointing to a general detrimental consequence of
increased protein levels rather than a specific effect of protein mutations
as the cause of motoneuron death in these models. In vitro studies have
beenmainly carried out in cancer cell lines that ectopically expressmutant
or wild-type proteins. These cell systems do not recapitulate the
complexity of the motoneuron and its microenvironment and/or imply
non-physiological levels of protein, which has hampered an accurate
molecular analysis of ALS pathogenesis.
Results
In this study, the authors take advantage of two powerful technologies to
develop a novel cell system to study the pathological mechanisms
underlying FUS-linked ALS. First, they generate patient-specific induced
pluripotent stem cells (PS-iPSCs), which carry the same FUS mutations
found in ALS-affected individuals and can be differentiated into
motoneurons. Then, by developing and optimizing a protocol of gene
editing – a methodology that allows the introduction of specific changes
in a cell’s genome – the authors generate additional FUS-mutant iPSC
lines that carry a severe mutation associated with juvenile ALS. By using
these new in vitro models, the authors show that the incorporation of
mutated FUS into cytoplasmic stress granules occurs in both
undifferentiated iPSCs and iPSC-derived motoneurons when these are
subject to various ALS-related cellular stressors (including oxidative
stress).
Implications and future directions
The iPSC-based in vitro model described here allows the evaluation of
the effects of patient-specific ALS-associated FUS mutations on ALS-
relevant cell types, e.g. motoneurons. It also helped to evaluate the
relevance of stress components in the pathogenesis of ALS. In addition,
these cell lines, derived from patient-cell reprogramming or generated by
site-directed mutagenesis, represent the ideal platform to dissect the
molecular and cellular defects downstream of FUS mutations that could
contribute to motoneuron death. Moreover, they will be instrumental for
in vitro drug screening, as previously shown with analogous iPSC-based
systems for other pathologies.
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patients (supplementary material Fig. S1D).We also checked for the
absence of mutations in the same genomic regions of the FUS and
TDP-43 genes in the iPSC line derived from the control donor
(iPSC-WT I; supplementary material Fig. S1E,F).
Taken together, this analysis confirmed that we successfully
reprogrammed somatic cells from patients with mutations inFUS and
TDP-43, generating bona fide patient-specific iPSCs (ALS-iPSCs).
In order to differentiate ALS-iPSCs into spinal cord populations
containing MNs, we adapted a previously established differentiation
protocol that includes an initial phase of neural induction followed by
the regional specification by retinoic acid (RA) and sonic hedgehog
(SHH) (Wichterle et al., 2002; Hu and Zhang, 2010). Initial
differentiation along the neuroectodermal lineage was triggered by
dual-SMAD signaling inhibition in feeder-free iPSC cultures
(Fig. 2A). This was followed by patterning with RA and
detachment of neural precursors that were cultured as floating
neurospheres. Further patterning with purmorphamine (PUR), an
SHH agonist, and replating on laminin-coated plates led to
differentiation of neuronal cells (Fig. 2B and supplementary
material Fig. S2A). A subset of these neural cells expressed
the specific MN markers HB9 (MNX1) and ISL1/2 (Fig. 2B-D
and supplementary material Fig. S2B,C). As expected for a
ubiquitous gene, FUS levels did not change upon differentiation
(supplementary material Fig. S2D). Analysis of the expression of the
specific markers OLIG2, HB9, ISL1 and CHAT in WT I and ALS
iPSCs suggested that there is no impairment of MN differentiation in
mutated lines (Fig. 2C,D and supplementary material Fig. S2C), as
previously described for SOD1 and other TDP-43 mutants (Dimos
et al., 2008; Bilican et al., 2012; Egawa et al., 2012).
Generation of amutant iPSCFUSP525L line byTALEN-directed
mutagenesis
It is known that FUSmutations associated with severe forms of ALS
localize in the C-terminal domain of the protein that contains the
nuclear localization signal (Dormann et al., 2010). Whereas ALS I
(FUSR514S/wt) and ALS II (FUSR521C/wt) patients developed the
disease inmid-late age, theALS IV (FUSP525L/wt) patient displayed a
juvenile onset of the disease. As we did not manage to obtain iPSCs
from FUSP525L/wt fibroblasts, we generated iPSC lines with this
mutation by genome editing. Our strategy, based on TALENs,
allowed us to introduce the P525L mutation in the endogenous FUS
locus of the iPSC-WT I line. The design, validation and optimization
Fig. 1. Generation of iPSC lines and ventral
spinal cord differentiation. (A) Immunostaining
of the pluripotency markers OCT4 (top panels),
SSEA4 (middle panels) and TRA1-60 (bottom
panels) in iPSCs derived from a healthy donor
(WT I) or three ALS patients carrying the mutations
in FUS or TDP-43 indicated above each panel.
Nuclei are counterstained with DAPI. Shown here
are representative images for WT I-clone 2; ALS
I-clone 2; ALS II-clone 34; ALS III-clone 2. Scale
bar for all panels: 100 μm. (B) RT-qPCRanalysis of
the indicated pluripotency markers in fibroblasts
(WT I), hESCs (RUES2 line) and iPSC clones.
Levels of mRNA are normalized to those of
hESCs. (C) RT-qPCR analysis of the expression of
endogenous and exogenous (i.e. carried by the
reprogramming vector hSTEMCCA) OCT4 in
untreated fibroblasts (F. D0), fibroblasts after
7 days of infection with hSTEMCCA (F. D7) and
iPSC clones. Levels of endogenous OCT4 mRNA
are normalized to those of iPSCs, whereas levels
of exogenous OCT4 mRNA are normalized to
those of F. D7. In B and C, representative analyses
for WT I-clone 5, ALS I-clone 1, ALS II-clone 34
and ALS III-clone 2 are reported. Similar analyses
for other clones are shown in supplementary
material Fig. S1.
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of the TALEN pair specific for FUS exon 15 (FUSC-term TALENs)
is shown in supplementary material Figs S3-S5. We took advantage
of the FUS C-term TALENs to produce iPSC FUSP525L lines devoid
of other genomic changes. The methodology, depicted in Fig. 3A,
was based on a two-step positive/negative selection strategy. In the
first step, homology-directed repair (HDR), stimulated by TALENs,
promoted the insertion of a selection cassette flanked by the
enhanced piggyBac (ePB) terminal repeats. The ePB is the
humanized version of an insect transposon (piggyBac, PB) that
transposes into a TTAA sequence, which is perfectly reconstituted
upon excision, leaving no changes in the host genome after multiple
transposition events (Lacoste et al., 2009). Thus, PB and its
derivatives can be exploited as excisable cassettes, leaving no
‘scar’ in the host genome upon transposition (Yusa et al., 2011). The
5′ arm of the HDR donor construct included the P525L mutation,
which is a C-to-T change in the second position of codon 525. The
selection cassette contained an independent promoter (PGK) driving
the expression of the PUΔTK bifunctional protein (Chen and
Bradley, 2000), conferring resistance to puromycin and sensitivity to
ganciclovir (GCV). After co-transfection with the FUS C-term
TALENs, we isolated individual puromycin-resistant clones. Two of
them contained the cassette inserted in one or both FUS alleles, thus
providing heterozygous and homozygous situations, respectively
(supplementary material Fig. S5). These clones were transfected
with amodified PB transposase [hyPB int(−)], unable to re-integrate
a sequence flanked by the PB terminal repeats (Li et al., 2013). In a
preliminary optimization experiment, such hyPB int(−) resulted in
the most efficient PB transposase for removing a selection cassette
from host cells (supplementary material Fig. S4). After hyPB int(−)
transient transfection, we counter-selected iPSCs retaining the
exogenous cassette and isolated individual iPSC clones. Real-time
PCR analysis on genomic DNA confirmed removal of the selection
cassette in one sub-clone for each line (supplementary material Fig.
S5A-E). PCRon genomicDNA confirmed that the selection cassette
was not re-integrated in a silenced form elsewhere in the genome
(supplementary material Fig. S5F). Before removal, the presence of
the selection cassette did not significantly affect FUS protein levels
(supplementarymaterial Fig. S5G). To confirm the single nucleotide
change in codon 525, the genomic region of interest was PCR-
amplified and sequenced. As shown in Fig. 3B, genomic DNA
sequencing revealed a double peak (C and T) in the heterozygous
sub-clone and a single peak corresponding to the C-to-T nucleotide
change in the homozygous sub-clone. Moreover, sequence analysis
of the genomic region surrounding the target site (about 1 kb)
Fig. 2. MN differentiation. (A) Schematic
representation of the differentiation protocol. SB,
SB431542 (Nodal/Activin inhibitor); DM,
dorsomorphin (BMP inhibitor); RA, all-trans retinoic
acid; PUR, purmorphamine (SHH agonist);
HUESM, differentiation medium; N2M neural
differentiation medium. (B) Immunostaining for the
pan-neuronal marker TUJ1 (top panels) and the
MN markers HB9 (middle panels) and ISL1/2
(bottom panels) in control and ALS iPSCs
differentiated for 34 days. Nuclei are
counterstained with DAPI. Scale bar for all panels:
20 μm. (C) Percentage of MN marker ISL1/2-
positive cells detected by immunostaining analysis
in differentiated iPSCs (34 days). Error bars
represent s.d. Statistical analysis (Student’s t-test)
showed no significant difference in the
differentiation ability of mutant iPSCs compared
with the WT I line. (D) RT-qPCR analysis of the
MN markers HB9, ISL1 and CHAT (choline
O-acetyltransferase) in control and ALS iPSCs
differentiated for 34 days. Histogram bars represent
the averages from six (WT I, ALS I and ALS II) or
four (ALS III) independent differentiations. Error
bars represent s.e.m. Statistical analysis (Student’s
t-test) showed no significant difference in the
differentiation ability of mutant iPSCs compared
with the WT I line.
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revealed the correct reconstitution of the TTAA sequence after the
PB transposase-mediated removal of the selection cassette and
confirmed that the TALEN-induced HDR event did not introduce
other genomic changes outside the mutated codon (supplementary
material Fig. S6A). Finally, analysis of possible off-target effects of
the TALENs confirmed the specificity of the utilized strategy
(supplementary material methods).
In summary, the combination of site-directed mutagenesis by
TALENs, followed by removal of the selection cassette by a
modified PB transposase, allowed the generation of two novel iPSC
lines, isogenic with our control iPSC line, containing the FUSP525L
mutation in heterozygosity or homozygosity. These new FUSP525L
mutant lines retained the ability to differentiate along the MN
lineage with efficiency comparable to controls, ALS I and ALS II
lines (supplementary material Fig. S2C).
As shown in Fig. 3C and D, the new FUSP525L mutant iPSC lines
expressed physiological levels of FUS protein and mRNA. Recent
reports by our lab and others have shown that an autoregulatory
feedback loop regulates FUS abundance (Zhou et al., 2013; Dini
Modigliani et al., 2014). In particular, FUS can bind its own pre-
mRNA and regulate alternative splicing of exon 7. Increased FUS
levels trigger exon 7 skipping during the splicing reaction and
production of an mRNA containing a premature termination codon,
which undergoes nonsense-mediated decay (NMD). According to
Fig. 3. Generation of FUSP525L iPSC lines by TALEN-directed mutagenesis. (A) Schematic of the TALEN/piggyBac combined strategy to generate the
FUSP525L mutant iPSC lines. On the top, theWT FUS locus and TALENs are depicted. Below, the HDR donor construct is schematized. PPGK, phosphoglycerate
kinase 1 promoter; PUΔTK, fusion between PuroR and DeltaTK (truncated version of HSV type 1 thymidine kinase). Yellow triangles represent enhanced
piggyBac (ePB) terminal repeats. The P525L mutation is indicated in red. The expected product of the homologous recombination and the FUS locus after
PB-mediated excision is shown at the bottom. Horizontal arrows indicate primers used for PCR amplification from genomic DNA of the fragments sequenced
in B. (B) Sequencing results from WT I iPSCs (top), iPSCs modified by TALEN-directed HDR after removal of the selection cassette (middle, heterozygous;
bottom, homozygous). The arrows indicate the targeted nucleotide in codon 525 (C, wild type; T, mutant). Further details are provided in supplementary material
Figs S3-S6. (C) Western blot analysis of FUS protein levels in iPSC lines used in this study. GAPDH is used as loading control. Densitometric quantification
of FUS protein, relative to WT I, is shown below. (D) RT-qPCR analysis of FUS total mRNA and alternatively spliced mRNA devoid of exon 7 in iPSC lines.
Quantification is relative to the levels in the WT I sample. (E) Immunostaining showing intracellular localization of WT and mutant FUS proteins in iPSCs.
Scale bar: 10 μm. (F) Quantification of the immunostaining signal, showing FUS intracellular distribution in iPSC lines. In D and F, significant difference from the
WT I was assessed by unpaired Student’s t-test; *P<0.05, **P<0.01, ***P<0.001.
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this model, a decrease in the nuclear levels of FUS should result in a
reduction of the NMD mRNA form. As shown in Fig. 3D, a strong
decrease of exon 7 skipping was indeed detected in FUSP525L/P525L
iPSCs and an intermediate decrease was observed in FUSP525L/wt,
suggestive of a direct correlation between the amount of skipping
and of nuclear FUS. The exon 7-devoid isoform represents a minor
fraction (1-2%) of total FUS mRNA (Dini Modigliani et al., 2014).
Thus, further reduction of this NMD isoform is not expected to
significantly affect FUS protein levels. Furthermore, other
mechanisms, such as repression by miR-200 (Dini Modigliani
et al., 2014) that is abundantly expressed in iPSCs (data not shown),
can blunt FUS protein levels.
FUS intracellular distribution was analyzed by immunostaining.
FUSP525L/wt showed a strong protein delocalization with a punctuate
cytoplasmic patterning (Fig. 3E and Fig. 4A). An even higher
delocalization was detected in the FUSP525L/P525L line. On the
contrary, the iPSC lines carrying the FUSR514S and FUSR521C
mutations showed a predominant FUS nuclear localization in both
undifferentiated iPSCs (Fig. 3E and Fig. 4A) and in iPSC-derived
ventral spinal cord cells (Fig. 5A), with only a minute cytoplasmic
delocalization (Fig. 3E). Quantification of the immunostaining
signals and cell fractionation indicated significant differences of
FUS cytoplasmic levels between controls and mutants, as well as
between strong and weak mutations (Fig. 3F and supplementary
material Fig. S6B).
Altogether, these data show that in genetic backgrounds
corresponding to those found in patients there is a progressive
increase in cytoplasmic FUS accumulation from the R514S and
Fig. 4. Confocal analysis of FUS localization in control and stressed undifferentiated iPSCs. (A,B) Immunostaining of FUS (red) and the SG marker TIAR
(green) in undifferentiated iPSCs in control (vehicle-treated) conditions (A) or upon 0.5 mM sodium arsenite-induced oxidative stress for 60 min (B). A variable
number of TIAR+ SGs could be observed in individual cells for all cell lines. Merge/nuclei panels show the combined signals of FUS, TIAR and DAPI. Scale
bar: 10 μm. Arrows indicate examples of co-localization of TIAR and FUS signals in the cytoplasm. (C) Quantification of the immunostaining, showing the
percentage of FUS signal in SGs. Statistically significant differences from WT I are indicated by asterisks (unpaired Student’s t-test; *P<0.05, **P<0.01,
***P<0.001). (D) Representative linescan analysis of the TIAR, FUS and DAPI signal intensity in SGs of the cells indicated by asterisks in B. The line drawn across
SGs and further analyses are shown in supplementary material Fig. S8.
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R521C mutations to the P525L. Notably, in the heterozygous line
FUSP525L/wt the amount of cytoplasmic FUS was reduced by half
compared with FUSP525L/P525L (Fig. 3E,F).
Endogenous FUSmutants display altered recruitment in SGs
in undifferentiated and differentiated iPSCs
Several kinds of cellular stress have been shown to induce
ectopically expressed mutant FUS protein recruitment into
cytoplasmic SGs (Bentmann et al., 2012). The re-localization of
mutant and WT FUS upon stress in undifferentiated iPSCs was first
tested with sodium arsenite (ARS) to mimic oxidative stress.
Immunostaining, analyzed by confocal microscopy, showed that the
iPSC-WT I line displays nuclear FUS localization both in the
absence (Fig. 4A) and in the presence of ARS (Fig. 4B). In
unstressed ALS I-FUSR514S/wt and ALS II-FUSR521C/wt cells, the
FUS signal is mainly nuclear, and upon ARS treatment only few
cytoplasmic speckles are visible (Fig. 4A,B). In heterozygous
FUSP525L/wt cells, a greater number of FUS+ speckles were induced
by ARS (Fig. 4B). Co-localization with the SG markers TIAR
(Fig. 4B) and PABP (supplementary material Fig. S7) indicated the
specific localization of mutant FUS in these structures. As the
antibody cannot distinguish between WT and mutant FUS, it is
impossible to establish whether only the mutant FUS protein is
present in SGs or whether the normal protein also co-localizes
inside the granules. Notably, in homozygous FUSP525L/P525L iPSCs,
whereas a strong and punctuate cytoplasmic delocalization of FUS
is observed in control conditions, upon ARS treatment the majority
of cytoplasmic signals concentrate into SGs (Fig. 4A,B).
Conversely, FUS remained nuclear restricted in stressed ALS III
iPSCs. These cells, carrying the TDP-43 mutation, serve as a further
control of a non-FUS ALS mutation. Quantification of the FUS
signal upon oxidative stress confirmed the accumulation of higher
protein levels within SGs in mutants compared with controls
(Fig. 4C). In the different mutants, the fraction of FUS localized in
SGs correlated with the degree of cytoplasmic delocalization
observed in unstressed cells (Fig. 3F). A linescan analysis showed
FUS localization, even if at low levels, in most of the SGs induced
by ARS in the weak mutants (FUSR514S and FUSR521C) (Fig. 4D
Fig. 5. Confocal analysis of FUS localization in control and stressed ventral spinal cord iPSC-derived cells. (A,B) Immunostaining of FUS (red) and the SG
marker TIAR (green) in iPSCs differentiated for 34 days, as in Fig. 2. (A) Control (vehicle-treated) conditions. (B) Oxidative stress induced by 0.5 mM sodium
arsenite for 90 min. Merge/nuclei panels show the combined signals of FUS, TIAR and DAPI. Arrows indicate examples of co-localization of TIAR and FUS
signals in the cytoplasm. (C) Immunostaining of FUS (red) and theMNmarker ISL1/2 (green) in iPSCs differentiated for 34 days and stressedwith 0.5 mM sodium
arsenite for 90 min. Merge/nuclei panels show the combined signals of FUS, ISL1/2 and DAPI. Scale bars: 10 μm in A,B; 20 μm in C.
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and supplementary material Fig. S8). The severe P525L mutation
caused much higher levels of FUS recruitment, which was
detectable in all SGs analyzed (Fig. 4D and supplementary
material Fig. S8). Taken together, these analyses showed that the
severity of the mutation, measured by the delocalization phenotype
in unstressed conditions, correlates with the ability of endogenous
FUS proteins to engage in SGs upon stress.
We next assessed whether recruitment into SGs of endogenous
FUSmutants was reversible and reproduciblewith different kinds of
stress. Upon removal of ARS and recovery in normal medium for
three hours, SGs were dissolved both in WT and mutant cells
(supplementary material Fig. S9). However, the kinetics of SGs
dissolution could be affected by the presence of mutant FUS, as
FUSP525L/wt cells displayed a greater number of SGs than WT cells
at earlier time points of recovery (supplementary material Fig. S9).
Heat shock, caused by a raise of the temperature to 44°C for 1 h,
caused SGs localization of the FUS mutant proteins, but not of WT
or ALS III (supplementary material Fig. S10). In the case of
hyperosmolar stress induced by sorbitol treatment (Sama et al.,
2013), we observed increased cytoplasmic FUS delocalization in
the mutants and, to a minor extent and at later time points, also in the
WT and ALS III (supplementary material Fig. S11). In this analysis,
we could not proceed beyond 25 min of sorbitol exposure, as iPSCs
survival was severely compromised after this time point. At 25 min,
SGs are not yet fully formed and the most evident effect of this stress
condition was on the cytoplasmic localization of FUS rather than on
its recruitment into SGs.
Overall, these data suggest the hypothesis that the ability to form
FUS+ SGs directly depends on the amount of cytoplasmic
delocalized FUS.
Finally, we studied FUS localization inWT and mutant lines after
differentiation to ventral spinal cord neural cells for 34 days (Fig. 2),
in control conditions and during stress. Our analysis confirmed SG
recruitment of endogenous FUS in the four mutants upon oxidative,
temperature and hyperosmolar stress (Fig. 5 and supplementary
material Figs S12-S16). In neural cells, similarly to what we
observed in undifferentiated iPSCs, the ability to recruit FUS into
SGs correlated with the amount of cytoplasmic delocalized protein
in unstressed conditions. In particular, the highly delocalized
FUSP525L mutant was detected in almost all TIAR+ granules in both
FUSP525L/wt and FUSP525L/P525L lines (Fig. 5 and supplementary
material Fig. S16). Co-staining with the specific marker ISL1/2
allowed us to visualize specifically MNs; notably, also in these cells
FUS+ SGs were present in the mutant, but not in the control
(Fig. 5C). In this analysis, we did not observe any difference in FUS
ability to aggregate in SGs in MNs versus surrounding neurons
(Fig. 5C). InWT differentiated cells, FUS recruitment was observed
in SGs only upon hyperosmolar stress (supplementary material
Fig. S15). Notably, in sorbitol-treated cells, a striking difference
between the FUS mutants and the WT was observed in the amount
of nuclear-localized FUS protein. Compared with WT cells, nuclear
FUS was strongly depleted in all FUS mutants (supplementary
material Fig. S15), suggesting a peculiar activity of this stress
stimulus in increasing cytoplasmic accumulation also of those FUS
mutants with a weak delocalization phenotype. In the TDP-43
mutant ALS III line, the localization of endogenous FUS closely
mirrored the WT control in all conditions tested.
In conclusion, our analysis showed preferential recruitment of
endogenous mutant FUS in SGs, in both proliferating iPSCs and
differentiated MNs. Upon exposure to oxidative or temperature
stress, FUS localization into SGs occurred exclusively in mutant
lines, although to different extents.
DISCUSSION
Currently, several in vivo systems of ALS have been produced,
including rodents, Drosophila melanogaster and Caenorhabditis
elegans (Shelkovnikova, 2013). Transgenic mouse models of ALS
display dose-dependent toxicity of FUS and TDP-43, usually
expressed under neuronal-specific promoters (McGoldrick et al.,
2013). Notably, overexpression of either mutant or wild-type
proteins seems to exert similar outcomes, pointing to a general
detrimental consequence of the alteration of protein levels, rather
than a specific effect of the mutations present in ALS patients, as the
cause of MN death in these models. Therefore, the ALS pathology
might be caused not only by mutations that alter the structure of
disease-associated proteins, but also by their altered levels. This
hypothesis is further supported by the recent finding of mutations
associated with severe forms of ALS not affecting the FUS coding
sequence but rather the 3′-UTR regulatory sequences (Sabatelli
et al., 2013). We recently showed that one of these ALS-associated
mutations disrupts an miRNA binding site, producing increased
levels of otherwise normal FUS protein (Dini Modigliani et al.,
2014). On the other hand, most in vitro studies with human cells rely
on non-neural or neuroblastoma cell lines, in which mutated FUS or
TDP-43 genes were overexpressed. Such systems do not recapitulate
the complexity of the motoneuron and its microenvironment and
imply non-physiological levels of protein.
In this study, we have successfully reprogrammed fibroblasts
from two ALS patients carrying the most common FUS mutations
(FUSR514S and FUSR521C). iPSCs from these patients can be
differentiated into cell types relevant for the disease, representing a
useful tool to model the ALS pathology in vitro. Moreover, as
fibroblasts from another severe FUS mutation (P525L) were not
available, wemade an effort in producing and optimizing a TALEN-
based approach to mutate the endogenous FUS gene in control
iPSCs. Our strategy was based on a two-step protocol that combines
HDR triggered by TALENs with seamless removal of the selection
cassette by an improved PB system [ePB terminal repeats used in
combination with the hyperactive int(−) transposase]. Importantly,
with the tools described here virtually any desired mutation can be
inserted in any gene of interest. Analysis of specific markers
suggested that WT and FUS mutant iPSCs can be differentiated into
MNswith comparable efficiency, even though it cannot be excluded
that some functional impairment in iPSC-derived MNs could occur.
In the future, electrophysiological analysis on differentiated MNs
will allow clarification of this aspect.
Most of ALS-linked FUS mutations are localized in the
C-terminal domain of the protein, which contains the PY nuclear
localization signal (Kwiatkowski et al., 2009; Gal et al., 2011).
Ectopic expression of ALS-associated FUS mutants in cell lines
showed an inverse correlation between the degree of cytoplasmic
mislocalization and the age of ALS onset in patients bearing the
corresponding mutations. Typically, mutations in codons 514 and
521 cause mild delocalization and are found in late-onset ALS,
whereas mutations in codons 525 (or 522), which strongly impair
nuclear import, are associated with juvenile ALS forms (Dormann
et al., 2010, 2012; Ito et al., 2010). Disruption of transportin-
mediated nuclear import, leading to mislocalization of FUS in the
cytoplasm, has been proposed as a causing determinant of the ALS
pathology (Vance et al., 2009; Dormann et al., 2010; Bosco et al.,
2010; Ito et al., 2010). The study of ALS physiopathology has been
tremendously advanced by the discovery that both FUS and TDP-43
are abnormally deposited in neuronal and glial cytoplasmic
inclusions in the majority of ALS and FTLD patients. A number
of recent studies have indeed shown that some FUS mutants,
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ectopically expressed in cell lines or in primary rodent neurons, are
recruited in SGs (Dormann et al., 2010; Bosco et al., 2010; Ito et al.,
2010; Bentmann et al., 2012; Baron et al., 2013), which are
cytoplasmic non-membrane-covered mRNP particles composed of
poly(A)+ mRNAs and RNA-binding proteins. On the other hand,
some SG markers have been found within pathological, FUS+,
cytoplasmic inclusions in ALS patients (Dormann et al., 2010;
Bäumer et al., 2010). These findings led to a model in which a
nuclear import defect, due to mutations in the NLS, causes FUS
recruitment into SGs, which, over time, might turn into pathological
inclusions, probably due to increased local concentration and/or
misfolding of FUS (Bentmann et al., 2013). An alternative model
considers SGs as protective structures that prevent FUS aggregation
in the cytoplasm. Over time, high levels of FUS expression would
overcome such protective function and result in the formation
of pathological inclusions (Shelkovnikova, 2013). Both models
need further experimental validation in appropriate experimental
systems. A crucial parameter to take into consideration is the
amount of FUS protein. When mutant FUS is overexpressed by
transient transfection, recruitment into SGs occurs in the absence of
external stress (Gal et al., 2011; Ito et al., 2010). However, FUS
mutants expressed by stably integrated inducible constructs
assemble into SGs only upon exposure to stressors (Bosco et al.,
2010). In these cells, lower levels of protein accumulation might be
more representative of the physiological situation. Recently, such
concentration-dependent behavior of mutant FUS has been
better characterized by correlating intracellular localization with
levels of ectopic expression. In particular, after reaching a given
concentration threshold, diffuse cytoplasmic mutant FUS
progressively aggregated, forming so-called FUS granules (FGs)
that subsequently assembled into FUS aggregates (FAs)
(Shelkovnikova et al., 2014). This evidence could represent an
important clue to understanding the formation of pathological FUS
inclusion during the progression of ALS, and it implies that the
study of pathological FUS should be carried out in cell model
systems expressing physiological levels of mutated proteins. To this
aim, a recent report used skin fibroblasts from ALS patients to study
mutant FUS incorporation in SGs (Vance et al., 2013). Interestingly,
mutant FUS sequestration in nuclear aggregates has been also
recently reported in patients’ fibroblasts (Schwartz et al., 2014).
However, despite FUS being ubiquitously expressed, fibroblasts
and most other cell types are spared by ALS, which instead
specifically affects MNs and their microenvironment. Therefore,
confirmation in neural cell systems such as those described here
would greatly substantiate observations made in fibroblasts.
Here, we took advantage of human iPSCs and their ventral spinal
neural derivatives to study the response to stress of different
endogenous FUS mutants expressed at physiological levels. We
showed that in normal growth conditions the FUSR514S and
FUSR521C mutant proteins were only minimally delocalized,
whereas FUSP525L was mostly cytoplasmic, with a punctuate
distribution in this compartment. Instead, when stress signals were
imposed on the cells, in all three cases the mutant proteins, with
different efficiency, depending on their delocalization phenotype,
were readily recruited into SGs. In particular, FUS in FUSR514S/wt
and FUSR521C/wt lines has a milder SG localization phenotype
compared with the FUSP525L/wt, which is typical of juvenile ALS. In
line with these data, the most severe phenotype was provided by the
FUSP525L/P525L line, in which FUS had the highest cytoplasmic
delocalization rate.
Notably, the wild-type protein markedly associated to SG only in
very extreme stress conditions, represented by long exposure to
hyperosmolar stress. In this case, however, a clear difference in SG
recruitment and intracellular localization of mutant and WT FUS
could be detected. These data indicate that in the genetic
background of the mutants, the amount of delocalized protein is
not able per se to induce SG recruitment that instead is produced
only upon a stress stimulus.
Our data suggest the relevance of stress components in the
ethiopathogenesis of ALS. Historically, oxidative stress has been
proposed as a potential pathogenic factor in ALS since the discovery
of mutations in the SOD1 gene, encoding for an antioxidant
enzyme, in fALS patients (Renton et al., 2014). More recently, other
kinds of stress have been also associated with the pathology.
A compound that has the ability to induce heat-shock response is
currently under investigation in a phase II clinical trial for ALS
(Kalmar et al., 2014). Moreover, it has been recently shown that
osmotic stress enhanced motoneuron degeneration in an animal
model of ALS (Therrien et al., 2013). Therefore, all stress
conditions tested in this work might be relevant for ALS.
As a future perspective, the iPSC-based in vitro model described
here, derived from patients by reprogramming or generated by site-
directed mutagenesis, might greatly improve our understanding of
the molecular basis of MN death and possibly help finding new
therapeutic targets for ALS. In particular, this model may be used to
better characterize the mechanisms that lead these particular FUS
mutant proteins to aggregate into SG. For instance, the analysis of
MNs expressing physiological levels of mutated proteins will help
to highlight irregularities in terms of SGs number, size and kinetics
of aggregation/disassembly upon cessation of stress, and the effects
of FUS mutations on general translation in normal conditions and
under stress.
MATERIALS AND METHODS
Generation and maintenance of human iPSCs
For ALS I, II and III, skin biopsies of informed donor ALS patients have
been collected in the Turin ALS center, Italy. Details on ALS II and ALS III
cases can be found in Chiò et al. (2011) and Borghero et al. (2011),
respectively. ALS I corresponds to case IV-7 in Chiò et al. (2009) (this
patient was diagnosed with spinal-onset ALS after publication of that
article). Dermal fibroblasts were generated from these explants and cultured
in fibroblast basal medium (FBM; Lonza) containing 15% FBS, 1× L-Glu
and 1× penicillin-streptomycin (all from Sigma-Aldrich). Whereas healthy
cultures could be established from ALS I, II and III, growth of fibroblasts
recovered from the ALS IV biopsy (kindly provided by Prof. M. Sabatelli,
Catholic University, Rome, Italy) was strongly impaired. We hypothesize
that reduced proliferation was due to contamination of the culture from
adipose and epidermis tissue, which might prevent fibroblast growth.
Control fibroblasts (WT I) from a healthy individual were kindly provided
by Dr A. Musarò, Sapienza University of Rome, Italy. For reprogramming
experiments, ALS and control fibroblasts in a 35 mm dish were infected in
serum-free conditions and in the presence of 4 mg/ml polybrene with the
lentiviral vector hSTEMCCA (Somers et al., 2010), carrying the four
reprogramming factors OCT4, SOX2, KLF4 and cMYC in a single
polycistronic unit. Seven days after infection, 50,000-100,000 fibroblasts
were seeded on a feeder layer of mytomycin C-treated primary mouse
embryonic fibroblasts (PMEF-CF; Millipore) in a 10 cm dish. The next
day, the medium was changed with HUESM [DMEM-F12+glutamax,
Life Technologies; 20% knockout serum replacement, Life Technologies;
1× non-essential amino acids (NEAA), Life Technologies; 1× penicillin-
streptomycin, 0.1 mM β-mercaptoethanol, both from Gibco] supplemented
with bFGF (10 ng/ml, BD Biosciences). Twenty days after infection, the
medium was replaced with Nutristem-XF (Biological Industries). Around
day 25, iPSC colonies were manually picked, fragmented and individually
passaged in a 12-well plate (passage 0, p0) coated with PMEF-CF cells. We
obtained iPSC colonies fromALS I, II, III andWT I fibroblasts. We failed to
reprogram ALS IV fibroblasts, probably due to their poor proliferation rate
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in culture, as active cell division is necessary for reprogramming to occur.
From each reprogramming experiment, typically 3-5 iPSC clones selected
by morphology (flat and uniform colonies with defined borders) were
expanded from p0. From p2-p3, established iPSC lines were maintained in
Nutristem-XF in plates coated with hESC-qualified matrigel (BD
Biosciences) and passaged every 4-5 days with 1 mg/ml dispase (Gibco).
The analysis of pluripotency markers shown in Fig. 1A,B was performed at
passage 2, 35-40 days after infection. For immunostaining analysis,
undifferentiated iPSCs were plated in matrigel-coated μ-chamber 12-wells
(Ibidi). Clones used in the experiments shown in Figs 2‐5 were: WT I
clone#1; ALS I clone#1; ALS II clone#34 and ALS III clone#2. These lines
were used in parallel throughout the study. We did not detect significant
differences between biological replicates, i.e. different iPSC clones derived
from the same patient or control, tested in parallel for selected experiments
(supplementary material Fig. S17).
Differentiation of iPSCs into ventral spinal cord neural cells
iPSCs were passaged (passage number ∼10-20) in 35-mm plates, and after
two days the medium was changed to HUESM supplemented with SMAD
inhibitors (SB/DM; 10 μMSB431542 and 2.5 μMdorsomorphin, both from
Miltenyi Biotec). This was considered day 0 (D0). From D4, in the presence
of SB/DM, the medium was gradually replaced with N2M (DMEM-
F12+glutamax; 1× N2 supplement, Life Technologies; 1× NEAA, Life
Technologies; 2 μg/ml heparin, Sigma-Aldrich): at D4, 75% HUESM and
25% N2M; at D6, 50% HUESM and 50% N2M; at D8, 25% HUESM and
75% N2M. From D10 to D14, differentiating neural progenitors were
cultured in N2M supplemented with 0.1 μM all-trans RA (Sigma-Aldrich).
At D14, neural rosette fragments were manually detached to generate
floating neurospheres, maintained in N2M (containing 1× B27, Life
Technologies) supplemented with 0.1 μM RA and 1 μM purmorphamine
(sc-202705, Santa Cruz). At D28, neurospheres were plated in poly-L-
ornithine (Sigma-Aldrich) and natural mouse laminin- (Invitrogen) coated
35-mm dishes for RNA extraction, or in poly-L-lysine- (Sigma-Aldrich) and
natural mouse laminin- (Invitrogen) coated glass coverslips for
immunostaining, in N2M supplemented with 10% FBS. The day after, the
medium was replaced with N2M supplemented with 10 ng/ml BDNF,
10 ng/ml GDNF and 10 ng/ml IGF (all from PreproTech), 1 μM cAMP and
200 ng/ml L-ascorbic acid (both from Sigma-Aldrich), 0.05 μM RA and
0.5 μM purmorphamine. Ventral spinal cord neural cells were collected for
RNA or fixed for immunostaining at day 34.
RT-PCR, RT-qPCR and western blot analyses
Total RNAwas extracted with the RNeasy kit (Qiagen). For RT-qPCR and
RT-PCR RNAwas retrotranscribed with the SuperScriptIII kit (Invitrogen).
As negative controls, minus-reverse transcriptase samples were included in
subsequent amplification reactions (not shown). For RT-PCR, cDNA was
used as template with the BioTaq DNA polymerase (Bioline). RT-qPCR
analysis was performed with SYBR Green QPCRMaster Mix (Qiagen) in a
7500 Fast Real-Time PCR System (Life Technologies) and calculations
were performed with the delta Ct method. In RT-qPCR analyses, the internal
control used was the housekeeping gene ATP5O (ATP synthase, H+
transporting, mitochondrial F1 complex, O subunit) for undifferentiated
iPSCs, or GAPDH for differentiation experiments. A complete list of
primers is provided in supplementary material Tables S1 and S2.
Western blot analysis of FUS protein levels was carried out with
NuPAGE 4-12% Bis-Tris gels (Life Technologies) in MOPS-SDS buffer
as in Morlando et al. (2012), using anti-FUS/TLS (Santa Cruz, sc-47711;
1:2000) and, as a loading control, anti-GAPDH (Santa Cruz, sc-32233;
1:3000) antibodies. Images were acquired with the ChemidocMP (Bio-Rad)
and protein levels quantified with the ImageLab software (Bio-Rad).
Immunostaining and confocal imaging
Cells were fixed in 4% paraformaldehyde for 20 min at room temperature
and washed twice with PBS. Fixed cells were then permeabilized with PBS
containing 1% BSA and 0.2% Triton X-100 and incubated overnight with
primary antibodies at 4°C. The primary antibodies used are: anti-OCT4 (BD
Biosciences, 611202; 1:500), anti-SSEA4 (Abcam, ab16287; 1:80), anti-
TRA1-60 (Life Technologies, 41-1000; 1:100), anti-FUS/TLS (Abcam,
AB84078; 1:500), anti-HB9 (DSHB, 81.5C10; 1:100), anti-Islet-1/2 (DSHB,
39.4D5; 1:50), anti-TIAR (BD Biosciences, 610352; 1:1000), anti-PABP
(Santa Cruz, SC-32318; 1:100) and anti-TUJ1 (Chemicon Mab, 1637;
1:100). The secondary antibodies used are: goat anti-mouse Alexa Fluor 488
(Invitrogen, A11029; 1:300), goat anti-mouse Cy3 (Jackson
ImmunoResearch, 115-165-003; 1:600), goat anti-rabbit Alexa Fluor 488
(Invitrogen, A11008; 1:200), goat anti-rabbit DyLight 549 (Vector
Laboratories, DI-1549-1.5; 1:300) and goat anti-rabbit Cy3 (Jackson
ImmunoResearch, 111-165-003; 1:300). DAPI (Sigma-Aldrich) was used
to label nuclei. For the immunostaining shown in Figs 1 and 2, as negative
controls mouse embryonic fibroblasts (MEFs) were stained in parallel with
iPSCs and showed no signal (data not shown). Cells in Figs 1 and 2 were
imaged with an Axioscope (Zeiss) microscope. Confocal images in Figs 3‐5
were acquired using an inverted Olympus iX73 microscope equipped with
an X-light Nipkow spinning-disk head (Crest Optics) and Lumencor Spectra
X LED illumination. Images were collected using a CoolSNAP MYO CCD
camera (Photometrics) and MetaMorph software (Molecular Devices) with
a 60× oil objective. For Fig. 5C a 20× objective was used. For each sample,
image stacks (26 images of 0.2-μm Z-step size) were acquired for each
wavelength. Images are shown as maximum-intensity projections of seven
planes. To count ISL1/2-positive cells, we used the Count Nuclei App of the
MetaMorph software, running the segmentation on the DAPI channel to
estimate the total number of cells and on the ISL1/2 channel to estimate the
total number of MNs. We counted 1000-6000 cells per line.
Quantification of nuclear/cytoplasmic and SG FUS distribution
and linescan analysis
All image analyses were performed with MetaMorph V7.8.0 software.
Before quantification, background signal was subtracted by statistical
correction for each FUS channel image. Resulting images were analyzed
with the integrated morphometry analysis (IMA) tool. For nuclear/
cytoplasmic distribution, a nuclear mask was generated in the DAPI
channel and then used in the IMA tool to measure FUS intensity in the same
nuclear region. Cytoplasmic FUS intensity was derived by subtracting the
nuclear intensity from the total intensity obtained with the region
measurements tool. This analysis was performed on at least 100 cells per
line, excluding dividing cells. Quantification of FUS inside SGs was
performed as follows: to generate a mask of the SGs we took advantage of
PABP as SG marker (supplementary material Fig. S7) as it allowed for a
more accurate segmentation of the SG signal than TIAR.We used the Count
Nuclei App to segment the PABP channel and generate an SG mask. To
avoid an overestimation of SG-FUS, the SGs overlapping the nucleus were
eliminated using a nuclear mask (created as described before). The corrected
SGmask was then used in the IMA tool to measure SG-FUS intensity. Total
FUS intensity was measured as described before. This analysis was
performed on at least 100 cells per line.
Linescan analysis was performed with the Linescan MetaMorph tool to
measure and graph the intensity values along a selected line in a 24-bit color
image. Data were graphed with separate traces for the red, green and blue
components. We used the multi-line tool to draw a line encompassing
multiple SGs.
TALEN-directed mutagenesis
Cloning of TALENs constructs targeting FUS exon 15 (FUS C-term
TALENs) was carried out following the GoldenGate strategy as described in
Sanjana et al. (2012) (Addgene TALEN Kit #1000000019). Details on the
TALEN constructs are provided in supplementary material methods. Donor
constructs for homologous recombination have been generated by cloning a
DNA fragment of 1130 bp, including the section of the FUS locus depicted
in Fig. 3, in the pBluescript KS(−) plasmid (Stratagene). Starting from this
construct, we generated the FUS-EGFP-T2A-PuroR donor (supplementary
material Fig. S3) and the FUS-PB-PGK-PUΔTK donor (Fig. 3A).
Oligonucleotides used for cloning are provided in supplementary material
Table S3. FUS C-term TALENs (1.5 μg each) and donor constructs (2 μg)
were co-transfected in iPSC-WTI cells (clone #1). All transfections were
carried out as follows: iPSCs were treated for 1 h with 10 μM ROCK-
Inhibitor (Y-27632, Sigma-Aldrich) to enhance survival, trypsinized, and
electroporated with a Neon Transfection System (Life Technologies) with
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100 μl tips in R buffer and the following settings: 1200 V, 30 ms, 1 pulse.
After transfection, iPSCs were seeded and cultured in presence of 10 μM
ROCK-Inhibitor for one day before switching to normal culture conditions.
Selection was carried out with 0.5 μg/ml puromycin for 7 days, and
surviving clones were individually passaged and characterized as described
in supplementary material Figs S3-S5. To remove the PB-PGK-PUΔTK
selection cassette, the cells were transfected with 5 μg of the hyPB int(−)
piggyBac transposase. After 7 days, 2 μg/ml ganciclovir (Sigma/Aldrich)
was added to the medium, and surviving clones were individually passaged
and characterized as described in supplementary material Fig. S5. Genomic
DNAwas isolated with the genomic DNA extraction kit (RBC Biosciences)
and the region surrounding FUS exon 15 was PCR-amplified with the
primers depicted in Fig. 3. In particular, the forward primer annealed outside
of the 5′ homology arm and the reverse primer in the 3′-UTR. Sequencing of
the DNA amplicon was carried out by Bio-Fab Research.
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